Compounds > aminotris(methylenephosphonato)diamminoplatinum (ii)

Page last updated: 2024-11-07

aminotris(methylenephosphonato)diamminoplatinum (ii)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aminotris(methylenephosphonato)diamminoplatinum (II): structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	147211
MeSH ID	M0177668

Synonyms (9)

Synonym
amdp
atmpdp
platinate(4-), diammine(((nitrilotris(methylene))tris(phosphato))(6-)-n,o)-, tetrahydrogen, (sp-4-3)-
cis-diammin(nitrilotris(methylphosphonato)-(2-)-o1,n1)platinum(ii)
117288-90-1
aminotris(methylenephosphonato)diamminoplatinum (ii)
diammine(nitrilotris(methylphosphonato)(2-)-o(1),n(1))platinum(ii)
DTXSID30151756
azane;[phosphonatomethyl(phosphonomethyl)amino]methylphosphonic acid;platinum(2+)

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (83.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.37 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pamidronate [no description available]	1.97	1	0	phosphonoacetic acid
thymidine [no description available]	1.98	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	1.97	1	0	indazole
thiazoles [no description available]	1.98	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ethylnitrosourea Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.	1.97	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; genotoxin; mutagen
ruthenium Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.	1.97	1	0	iron group element atom; platinum group metal atom
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	1.97	1	0	titanium group element atom
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	1.98	1	0	organic bromide salt	colorimetric reagent; dye
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	1.98	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	1.98	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	1.98	1	0	divalent inorganic anion; phosphite ion
olpadronic acid [no description available]	1.97	1	0
diethoxy-(1-phenyl-1,3-butanedionato)titanium (iv) [no description available]	1.97	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Deficiency, Mental [description not available]	0	2.31	1	0
Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)	0	2.31	1	0
Bone Cancer [description not available]	0	2.38	2	0
Cancer of Lung [description not available]	0	1.98	1	0
Osteogenic Sarcoma [description not available]	0	2.67	3	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.38	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	1.98	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.67	3	0
Adenocarcinoma, Basal Cell [description not available]	0	1.98	1	0
Cancer of Colon [description not available]	0	1.98	1	0
Colorectal Cancer [description not available]	0	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	1.98	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	1.98	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	1.98	1	0
Cancer of Ovary [description not available]	0	1.97	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	1.97	1	0
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	0	1.97	1	0